Background: There are considerable knowledge gaps concerning different estrogen and progestin formulations, regimens, and modes of administration of menopausal hormone therapy (HT) and the risk of breast cancer. Our objective was to assess the different treatment options for menopausal HT and the risk of breast cancer.
Introduction
Menopausal hormone therapy (HT) alleviates menopauserelated symptoms and prevents osteoporotic fractures [1] , but HT has been associated with an increased breast cancer risk [2] . In two large prospective studies, short-term use of estrogen-only therapy (ET) did not increase the risk of breast cancer, yet longerterm use did [3, 4] . Current recommendations state that HT for up to 3-5 years could be beneficial for women <60 years, while the excess risk of breast cancer in women >70 years is a relative contraindication [5] , and that duration of HT should not exceed 3-5 years.
It is well-established that adding progestogens to HT reduces the excess risk of endometrial cancer [6] , however, several studies suggest that estrogen þprogestogen (EPT) formulations increase breast cancer risk [4, [7] [8] [9] [10] [11] . Data are limited regarding the effects of different types of estrogens and progestogens, formulations, regimens, and modes of administration of HT on breast cancer risk [2] . Using cutaneous (patch) estrogens, which avoid the first-pass effect in the liver, may avoid the increased risk observed with oral use, but there is a need for studies examining this potential difference.
After publication of a trial demonstrating an increased risk of breast cancer [12] , use of HT has dropped dramatically over the last 15 years [13] . The aims of this study were to assess the risk of breast cancer following contemporary HT while taking advantage of the wide range of HT regimens used in Sweden and to identify regimens that minimize any excess risk of breast cancer.
Methods
All women with at least one dispensed HT prescription between 1 July 2005 and 31 December 2012 were identified (supplementary Methods, available at Annals of Oncology online) [14] . These ever HT users were group-level matched 1 : 3 on year of birth to women with no HT prescriptions during this study period (never-users) (supplementary Methods, available at Annals of Oncology online). Both HT users and non-HT users were excluded if they were younger than 40 years, or if there was a history of malignancy (except nonmelanoma skin cancer) identified from the Swedish Cancer Register at the time of their first HT prescription (users) or start of the study period (non-HT users).
The majority of the ever-users had at least one prescription in 2005 (N ¼ 173 465; 59.8%; supplementary Table S1 , available at Annals of Oncology online) and had an unknown starting date of HT.
Follow-up
The personal identity number allowed linkage to the nationwide Swedish registries of cancer, patient data, and causes of death (supplementary Methods, available at Annals of Oncology online). The Patient registry was used to ascertain ever parous (based on record of delivery), hysterectomy, and co-morbidities that might confound the association between HT and breast cancer (e.g. osteoporosis, smoking-related diseases, alcohol-related diseases, thrombotic events, obesity, and diabetes mellitus). The study was approved by Regional Ethical Review Board in Stockholm (2014/1291-31/4), and the need for informed consent was not required.
Statistical analysis
Conditional logistic regression, taking into account clustering by the exact-matching variables, was used for analyses evaluating ever use versus never use since the group-matching procedure neutralized the effect of follow-up time, and no substitute date was assigned for the never-users to assess the duration of follow-up. Multivariable models were also adjusted for all eight matching variables as well as osteoporosis, providing adjusted odds ratios (OR) and 95% confidence intervals (CIs). These analyses compared HT ever-users, current-users, and past-users with never-users for the whole study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) .
To assess the relation between duration of HT and breast cancer risk, multivariable Cox regression models provided hazard ratios (HRs) and 95% CIs. Multivariable models were adjusted for the matching variables (using age at first prescription instead of year of birth), osteoporosis, duration of treatment, and formulations and regimens of HT if appropriate (restricting the analysis to those not switching therapy Among women using EPT, continuous EPT was more common (60.0%, N ¼ 92 381) than sequential combinations (18.3%, N ¼ 28 263). Additionally, testosterone-derived progestogens were administered more frequently (55.6%, N ¼ 85 659) than progestogen-derived progestogens (30.7%, N ¼ 47 308). The most commonly used EPT was testosterone-derived progestogens administered continuously (34.6%, N ¼ 53 360).
Menopausal HT and overall risk of breast cancer
Compared with never-users of HT, ever-users did not have an increased risk of breast cancer (OR ¼ 1.02; 95% CI 0.99-1.05) ( Table 1) . However, there were important differences in risk of breast cancer by type of formulation, age at initiation, as well as current versus past use. Compared with never-users, current users had an increased risk of breast cancer (OR ¼ 1.38, 95% CI 1.33-1.43), and the association was stronger for EPT users (OR ¼ 1.77, 95% CI 1.69-1.85) than ET users (OR ¼ 1.08, 95% CI 1.02-1.14). Among current users of EPT, there was increasing risk of breast cancer with later age of initiation, and among women who began HT use at age 70 or later, current users of EPT had a more than threefold increased risk of breast cancer compared with neverusers (OR ¼ 3.59, 95% CI 3.30-3.91). In contrast, past users of HT were at a decreased risk of breast cancer compared with neverusers (OR ¼ 0.75, 95% CI 0.72-0.79). This inverse association was stronger for past use of estrogen-only HT (OR ¼ 0.63, 95% CI 0.60-0.67) than for EPT (OR ¼ 0.89, 95% CI 0.84-0.93).
Duration of menopausal HT and risk of breast cancer
The analyses of duration of HT were restricted to women with a first recorded prescription earliest in 2006 (Table 2), or earliest  2007 (supplementary Table S3 , available at Annals of Oncology online). Comparing ever-users exposed 12 months to those exposed <12 months, showed no increased risk of breast cancer (HR ¼ 1.03, 95% CI 0.91-1.16). However, when examining specific HT types, the risk of breast cancer was increased among women using EPT 12 months (HR ¼ 1.17, 95% CI 1.00-1.38), but not for ET users (HR ¼ 0.89, 95% CI 0.74-1.07). No evidence for interaction between age and duration of use (as continuous variables) was found among current-users (P ¼ 0.240 according to likelihood-ratio test).
Estrogen-formulations of menopausal HT and risk of breast cancer
Among estrogen-only HT users, different estrogen formulations were differentially associated with risk of breast cancer (supplementary Table S4 , available at Annals of Oncology online). Ever-users of ET had an overall decreased risk of breast cancer compared with never-users (OR ¼ 0.83, 95% CI 0.80-0.87), while current-users had a modestly increased risk (OR ¼ 1.08, 95% CI 1.02-1.14). However, specific formulations of estrogens were associated with an increased risk of breast cancer. Ever-users of conjugated estrogens had a 33% increased risk (OR ¼ 1.33, 95% CI 1.00-1.77) and ever-users of tibolone had a 15% (OR ¼ 1.15, 95% CI 1.06-1.25) increased risk of breast cancer compared with never-users. The association was stronger among current-users of conjugated-estrogens (OR ¼ 4.47, 95% CI 2.67-7.48) and tibolone (OR ¼ 1.68, 95% CI 1.51-1.87) although based on much smaller groups.
Progestogen-formulations of menopausal HT and risk of breast cancer
The risk of breast cancer for different formulations and usagepatterns of progestogens for women using combined EPT therapy is presented in supplementary Table S4 , available at Annals of Oncology online). Among current-users, the magnitude of risks were higher among all progestogen-users, in particular for testosterone-derived continuous combinations (OR ¼ 2.66, 95% CI 2.49-2.84) and progesterone-derived continuous combinations (OR ¼ 2.18, 95% CI 1.99-2.40).
Mode of menopausal HT administration and risk of breast cancer
The associations between oral versus cutaneous HT and breast cancer are presented in supplementary 
Discussion
This study evaluating the association of contemporary menopausal hormone therapies with breast cancer risk showed that different HT regimens have different effects on breast cancer risk. As previous studies of older generations of HT have reported [4, Current user is defined as at least one prescription during the last 6 months of follow-up. a Multivariate analyses adjusted for hysterectomy, ever parous, thrombotic events, year of birth, smoking-related diseases, alcohol-related diseases, obesity, diabetes mellitus, and osteoporosis.
7, 15-17], this study found that current use of EPT was associated with an increased risk of breast cancer. Estrogen-only HT was also associated with an increased risk, but the magnitude of association was much more modest. This study has a number of strengths, including the large sample size, population-based study design, and contemporary formulations of HT. In addition, the Swedish Prescribed Drug Registry allowed for high quality and detailed information on HT formulations and nationwide coverage. The unique matched cohort design allowed for HT users and nonusers to be balanced on several potential confounders. This group-level matching enabled us to create two groups with a similar probability of being treated with HT, a similar approach as used in propensity-scoring matching, therefore limiting the risk of selection bias and confounding. This method also takes into account the problem with exposure time for never-users (who do not have a start date of exposure); yet the relative effect of duration of use was evaluated among different groups of HT users. Additional adjustment for the matching variables in all analyses did not change the results, indicating the matching was successful.
This study also has some limitations. The main limitation is that the Swedish Prescribed Registry did not begin until 2005. This resulted in incomplete information on first date of prescription and as a result also incomplete data on duration of use. In secondary analyses, we restricted analyses to new prescriptions during the study period. In general, although the number of cases of breast cancer dropped, we found results that were very consistent with the main analysis. Additionally, we were limited in our ability to assess longer durations of use. Although older studies have demonstrated that longer duration of HT increases the risk of breast cancer, we could not assess this in the present cohort. We were also limited by availability of data coming from Swedish registries. We used the Patient Registry to control for potential confounders; however, we were unable to adjust for a number of known breast cancer risk factors such as reproductive factors and body mass index. Additionally, information on some factors such as hysterectomy and parity may be under ascertained for those occurring before the start of the registry, or may only reflect more severe cases (e.g. obesity). However, previous studies, which present both adjusted and unadjusted estimates suggest that confounding by established breast cancer risk factors is minimal [11] . Additionally, we were unable to evaluate interactions between HT and factors such as body mass index and age at menopause, which others have reported with standard HT doses [4, 10] . We were also unable to assess the association by family history, benign breast disease or tumor estrogen receptor status, since the Cancer Registry did not contain this information. A national mammography screening program has been established in 1994 in Sweden, inviting all women aged 40-74 years every 18-24 months [18] [19] [20] . Although 80% attend the screening [19] , women on HT may be more likely to attend but no information on screening attendance was available. Unfortunately, we did not have information on the starting age of menopause [21] , in particular for the nonusers. Among our HT users, 14.4% was younger than 50 at the time of their first prescription. Although we used age 40 to avoid premature menopause, some nonusers may not have started menopause yet giving them a higher probability of breast cancer compared with menopausal women of the same age [22] . This may explain some of the apparent protective effects of HT in the younger age group. When those younger than 50 years at the start of the study period were excluded, the OR of breast cancer among the youngest group of current users was 1.10 (95% CI 1.05-1.15) compared with 1.02 (95% CI 0.99-1.05) in the whole youngest age-group.
Since the publication of WHI results in 2002, demonstrating an increased risk of breast cancer with EPT, prescription patterns for estrogen plus progestogen therapies have declined [23] , and formulations and patterns of use have changed [24] . The standard dose of estrogens in oral HT used in the WHI trial and before 2001 included 0.625 mg conjugated equine estrogens. Guidelines now recommend low-dose and short-term use of oral HT [25, 26] . Additionally, transdermal HT have also been advocated [27, 28] . In line with these recommendations, the prevalence of women prescribed standard dose oral HT has declined in the USA and Europe, while use of low-dose oral formulations as well as transdermal preparations have increased [29] [30] [31] [32] [33] . One of the main contributions of the current study is the ability to examine different types of estrogens and progestogens, formulations, regimens, and modes of administration. Combined EPT regimens with continuous progestogens were associated with a more than threefold increased risk compared with never users. In contrast, the sequential formulations were only suggestively associated with risk. These results have important public health implications. They suggest that for women interested in taking HT, sequential formulations are less associated with breast cancer risk compared with other EPT.
We also found that current cutaneous use of EPT was associated with an increased risk of breast cancer. Although cutaneous use of EPT had a slightly lower risk than was observed with oral HT, this study provided much needed information on the risks associated with cutaneous HT. These findings argue against the hypothesis that cutaneous HT may not be associated with breast cancer to the same extent as oral HT since it avoids the first-pass effect in the liver (cutaneous estrogen may not increase sex hormone-binding globulin to the extent that oral preparations do) [34] . We also observed an inverse association with past use of HT, which is consistent with some prior studies [2, 11] , but not all [16] . It has been hypothesized that past-users are more likely to have shorter durations of use than current-users, and that these women may be using HT for the short-term relief of menopausal symptoms. Moreover, women who initiate HT tend to be leaner and may be at a reduced risk of developing breast cancer [35] [36] [37] .
In conclusion, this large population-based study found that risk of breast cancer differed substantially by various contemporary formulations of HT. These data fill important gaps in our knowledge and may help clinical decision-making when considering the benefits and potential harms of HT for relief of menopausal symptoms.
